Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,359.41
(
-0.66%
)
US TECH 100
27,992.40
(
-1.29%
)
Dow Jones
49,433.71
(
-0.19%
)
Brent Oil
108.91
(
1.34%
)
Bitcoin
76,265.56
(
-1.48%
)
News Focus
News Focus
Post# of 257581
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122989
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Tuesday, 01/04/2022 11:01:42 AM

Tuesday, January 04, 2022 11:01:42 AM

Post# of 257581
ASMB 2022 newsflow:

https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-outlines-anticipated-2022-pipeline

Note: ASMB nominally has three HBV core inhibitors: i) VBR (f/k/a ABI-H0731), which is in various phase-2 trials using 3-drug regimens, but failed badly in a 2-drug trial with a nuc (#msg-159327881); ii) ABI-H3733 (in phase-1a); and iii) ABI-4334 (preclinical).

A fourth core inhibitor, ABI-H128, was axed due to liver tox (#msg-165734953).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today